Member Info for VincentVega

https://youtu.be/Y5WBW-X7S9Y

You’ll find that subject (question) is raised by Allan Syms in his video interviews.

Worth a watch.

Aidan,

20p?

Mazik.

The RNS is irrelevant.

I also did dummy buys. Couldn’t get a quote for anything larger than 20k.

Conversely I tried 100k dummy sell. I only got a price for 20k.

It works both ways depending on MMs.

Unless one of the significant shareholders sell or a TR1 is issued for somebody who breaks the 3%, there are 179m available to trade. That doesn’t take into account any shareholders hovering under 3%. To try and establish a number on the latter would be pure guesswork on my part.

I make it 170m in nominee accts.

It’s simply a 5min extension when price matching can’t be met in a auction.

Confirmation of delivery to Corepath of the optimised immuno assays comes a couple of steps before validation in my limited knowledge of this industry.

So on that basis, you’d be better off listening to Neil than me.

Whether you are FTSE 100, 250, main listed or Aim, there is no such thing as an entitled mcap or sp.

Open ended merger, if ever then.

Ciz1b is present and detectable through all 4 stages of lung cancer.

https://www.youtube.com/live/sHLMtj54es0?feature=share

32 mins in, watch until the end of the Cizzle interview.

Yes it would, but given today’s RNS, I’d be surprised if it’s tomorrow or even this week.

https://www.bdo.co.uk/en-gb/insights/industries/aim/aim-directors-remuneration-report

Whilst the above report looks at AIM listed CEO remuneration it may serve as a useful benchmark.

Further; even if as has been suggested, our CEO is only contracted for 2-3 days per week, his salary is a fraction of that of other CEOs. If you factor in eoy bonuses, for those-businesses that may be profitable or not, Allan is vastly underselling himself.

Far too many CEOs of small businesses overpay themselves with eye watering salaries. I’m happy that I’m invested in a Company whose CEO is managing costs and aligning his financial interests with that of shareholders.

Other CEOs should take note.
Imho

Thank you RKB.

Allan suggested in one of his interviews that Director salaries were low.

I’ve tried to establish the salaries of the 3 main Directors this morning, to no avail.

Can anyone point me in the right direction please.
tia.

Something may have leaked somewhere to instigate these moves.

Surely not all down to fomo.

Given that Dawn has dedicated a serious portion of her life to understanding this protein, I’d hazard that her ambitions are anchored in a far loftier valuation than 7.5p.

Given product validation, she wouldn’t be able to sell at anywhere near 7.5p if you know what I mean.

Not a ramp.

Mazik

We don’t need FDA approval in order to go to initial commercialisation. We just need Corepath to grant it LDT status under their licensing authority. That gives us access to 22 States in the US for the test to be rolled out. A sort of shortcut/shoehorn to FDA approval further down the road.

I remember doing some research during the pandemic. I came across Novacyt whose sp at the time was 60p. When I pulled up the chart it was clear that they had already 9 bagged at that point.

Did I really want to risk buying into a spike?

Ha ha, if only…………